421 |
Synthesis, Characterization, and Biological Activity of Mono- and Bisimidazolium SaltsWagers, Patrick Owen 10 September 2015 (has links)
No description available.
|
422 |
Cis-acting Genetic Variants that Alter ERCC5 Regulation as a Prototype to Characterize cis-regulation of Key Protective Genes in Normal Bronchial Epithelial CellsZhang, Xiaolu January 2016 (has links)
No description available.
|
423 |
Restriction landmark genomic scanning to identify novel methylated and amplified DNA sequences in human lung cancerDai, Zunyan January 2002 (has links)
No description available.
|
424 |
Smoking behavior after a diagnosis of lung cancerBrowning, Kristine Kihm 20 September 2007 (has links)
No description available.
|
425 |
Exploitation and Mechanistic Validation of Drug-combination Strategies to Overcome EGFR-inhibitor resistance in NSCLC cellsWang, Yu-Chieh January 2008 (has links)
No description available.
|
426 |
Mechanisms of Receptor-Mediated Hypercalcemia in Human Lung Squamous Cell CarcinomaLorch, Gwendolen 14 July 2009 (has links)
No description available.
|
427 |
COVID-19 Perceptions and Responses of Advanced Lung Cancer Patients vs. Non-Cancer Controls: A Group Comparison DesignCoker, Clarence Aitanokhai 25 July 2022 (has links)
No description available.
|
428 |
Impact of local recurrence on cause-specific death after stereotactic body radiotherapy for early-stage non-small cell lung cancer: dynamic prediction using landmark model / 早期非小細胞肺癌に対する体幹部定位放射線治療後の局所再発が疾患特異死亡に及ぼす影響:ランドマークモデルによる動的予測Ueki, Kazuhito 23 March 2022 (has links)
京都大学 / 新制・課程博士 / 博士(医学) / 甲第23785号 / 医博第4831号 / 新制||医||1057(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 伊達 洋至, 教授 中本 裕士, 教授 鈴木 実 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM
|
429 |
Targeting Tyrosine Kinase Drug Resistance Mechanisms and Metastatic Pathways in Brain TumorsAljohani, Hashim M. 27 September 2020 (has links)
No description available.
|
430 |
Analysis of clinical and radiomic factors associated with intermediately-categorized pulmonary nodule lung-rads risk progressionHurlburt, Cameron G. 29 September 2022 (has links)
Lung cancer currently has the greatest mortality rate of cancer patients of all sexes in the United States (Torre et al., 2016). Low-dose CT scans are utilized for lung cancer screening in patients who fall within the NLST entry criteria (Sanchez-Salcedo et al., 2015). The original criteria for screening were age over 55 and pack-year over 30, which were recently changed to age 50 and pack-year over 20 in 2021. The study population in this paper utilized the original criteria.
A system developed and copyrighted by the American College of Radiology (ACR) referred to as the Lung CT Screening Reporting and Data System (Lung-RADS) has implemented a standardized method of classifying and interpreting lung cancer chest CT screening results. Lung-RADS has a scoring system which is scaled 1 – 4x (Pinsky et al., 2015) The likelihood of malignancy based on nodule appearance, diameter, and presence of growth comprise the components of which score is given (Chung et al., 2017). Lung-RADS 2 scored nodules are benign nodules and patients follow up for another CT in a year. Lung-RADS 3 nodules are probably benign nodules; however, they do have a low-risk of malignancy. It is known that a select few of these relatively benign appearing nodules will turn out to be malignant. Lung-RADS 4 nodules have a >5% chance of malignancy and can be confirmed through pathology.
In this project, a retrospective chart review analyzing patient demographics and pulmonary health history will be correlated to lung-RADS risk likelihood of malignancy. Machine learning will also be utilized to study and analyze radiographic factors associated with the sample. The CT scans of patients who previously scored in an intermediate category will be compiled and analyzed to determine potential common demographical, clinical and radiomic factors which will hopefully allow intermediately categorized nodule indicators to be used to detect cancers earlier and to more accurately classify lesions into benign or malignant categories.
In all, the goal of this research is to determine common clinical, demographic and radiomic factors of patients who were deemed intermediate risk and then progressed to a higher categorization. The importance of expanding current risk factors for discrimination of benign from malignant will also be analyzed, along with those specific risk-factors within Lung-RADS intermediately categorized nodules. The characteristics and baseline co-morbidities of RADS 2 and 3 lung cancer patients by follow-up CT results, progression to RADS-4 on follow-up CT and lung cancer diagnosis will be compiled and exemplified.
|
Page generated in 0.02 seconds